International Journal of Medical and Pharmaceutical Research
2022, Volume-3, Issue-2 doi: 10.5281/zenodo.10260965
Original Article
Comparison of Platelet Rich Plasma Injection and Intraregional Steroid Injection In the Management of Plantar Fasciitis: A Prospective Study of 40 Patients
Published
Dec. 11, 2022
Abstract

Introduction: Plantar fasciitis is most common cause of chronic heel pain and it’s typically aggravated on weight bearing after a period of rest .Its diagnosis is mainly clinical and there are various modalities of treatment of this condition. We compare platelet rich plasma injection and intraregional steroid injection in long term pain relief in plantar fasciitis.

Material and Methods: Patient of plantar fasciitis with symptoms lasting more than 6 weeks were included in study. Patients with other coexisting disease like diabetes mellitus, vascular insufficiency, hypothyroidism and previous surgery were excluded from disease. In this prospective double-blind study, 60 patients who fulfilled the criteria were divided randomly into two groups. Patients in Group A received PRP injection and those in Group B received steroid injection. Patients were assessed with visual analog scale (VAS) and American Orthopedic Foot and Ankle Society (AOFAS) score. Assessment was done before injection, at six weeks, three months and six months follow-up after injection.

Results : Mean VAS score in group A decreased from 6.14 to 1.10 after receiving PRP injection while in group B , Mean VAS score decreased from 8.20 to 1.40 at 3 months follow up. There was also statistical significant improvement in AOFAS score in PRP injection group as compared to steroid group at 6 months follow up.

Conclusion : Both PRP and Steroid have benefit in relieving pain for short term however long term benefit is more seen in patient receiving PRP injection.

Recommended Articles
Loading Image...
Volume-3, Issue-2
Citations
2719 Views
139 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved